Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label MK-8294 monotherapy study in advanced solid tumors
NL-OMON60454Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MK-8294 in endometrial cancer (EC), bladder cancer, head and neck squamous cell carcinoma (HNSCC) and 3 more, sponsored by Merck & Co. Started Jul 2025; status: recruiting.
02
Drugs
MK-8294
03
Conditions
endometrial cancer (EC)bladder cancerhead and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NL-OMON60454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60454.